All In MedTech

FDA Clearance Tracker · P190009-S010

OPRA Implant System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 12, 2026

Approved

Time to decision

167 days

Received Sep 26, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P190009-S010
Device name
OPRA Implant System
Applicant
Integrum AB
Applicant location
MöLndal
Received
Sep 26, 2025
Decided
Mar 12, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P190009

Device type

Device class
Class III

Every decision under product code PJY

FDA's approval statement

As written in FDA's record.

approval for revisions to the device labeling that was updated to include information on the Post-Approval Study (PAS), TFAOS PAS, for the OPRA Implant System

Source documents

Other decisions for Integrum AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.